| scholarly article | Q13442814 |
| P50 | author | Robert Califf | Q19281782 |
| Jonathan L. Halperin | Q6273626 | ||
| Robert J. Desnick | Q7345862 | ||
| Patrice Delafontaine | Q37387470 | ||
| Robert D McBane | Q56850301 | ||
| Margaret C. Fang | Q124660446 | ||
| P2093 | author name string | Henny H Billett | |
| Scott E Kasner | |||
| Samuel Z Goldhaber | |||
| Stephen E Kimmel | |||
| Julie A Johnson | |||
| Thomas L Ortel | |||
| Nancy L Geller | |||
| Emile R Mohler | |||
| Michael D Caldwell | |||
| Benjamin French | |||
| Charles S Eby | |||
| Sherif Z Abdel-Rahman | |||
| Yves D Rosenberg | |||
| Richard B Horenstein | |||
| Nita A Limdi | |||
| Jeffrey L Anderson | |||
| Jonas H Ellenberg | |||
| Brian F Gage | |||
| Robert C Pendleton | |||
| Scott M Stevens | |||
| Steven Yale | |||
| Vinay Shah | |||
| James A S Muldowney | |||
| Jaspal Gujral | |||
| COAG Investigators | |||
| Rosemary A Madigan | |||
| P2860 | cites work | Genetics and cardiovascular disease: a policy statement from the American Heart Association. | Q30418104 |
| Estimation of the warfarin dose with clinical and pharmacogenetic data | Q33410725 | ||
| Integration of genetic, clinical, and INR data to refine warfarin dosing | Q33550741 | ||
| Debating clinical utility | Q33832923 | ||
| Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial | Q34397841 | ||
| Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study | Q34617523 | ||
| Idraparinux versus standard therapy for venous thromboembolic disease | Q34687116 | ||
| Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial | Q35037021 | ||
| Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design | Q35218128 | ||
| Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial | Q35555922 | ||
| Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial | Q36190185 | ||
| The future of warfarin pharmacogenetics in under-represented minority groups | Q36294461 | ||
| A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose | Q36835176 | ||
| Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans | Q36882317 | ||
| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin | Q37196787 | ||
| A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). | Q38474432 | ||
| Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation | Q38496934 | ||
| CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. | Q40174813 | ||
| The long and winding road to warfarin pharmacogenetic testing. | Q43005079 | ||
| Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). | Q43104385 | ||
| Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial | Q45300095 | ||
| Pharmacogenetics--tailoring treatment for the outliers | Q46116659 | ||
| Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation | Q46910098 | ||
| A method to determine the optimal intensity of oral anticoagulant therapy. | Q51058560 | ||
| Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. | Q51467614 | ||
| A randomized controlled trial of genotype-based Coumadin initiation. | Q51588530 | ||
| Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy | Q71264573 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | (RS)-warfarin | Q407431 |
| P304 | page(s) | 2283-2293 | |
| P577 | publication date | 2013-11-19 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | A pharmacogenetic versus a clinical algorithm for warfarin dosing | |
| P478 | volume | 369 |
| Q34436061 | 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism |
| Q40391326 | A Framework for Prioritizing Research Investments in Precision Medicine |
| Q38429749 | A Knowledge-based System for Intelligent Support in Pharmacogenomics Evidence Assessment: Ontology-driven Evidence Representation and Retrieval |
| Q28468503 | A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy |
| Q35888757 | A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics |
| Q35879764 | A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation |
| Q90068670 | A Simple Formula for Predicting the Maintenance Dose of Warfarin with Reference to the Initial Response to Low Dosing at an Outpatient Clinic |
| Q38777644 | A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. |
| Q36433323 | A multi-factorial analysis of response to warfarin in a UK prospective cohort |
| Q49963027 | A prediction study of warfarin individual stable dose after mechanical heart valve replacement: adaptive neural-fuzzy inference system prediction. |
| Q38630707 | A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system |
| Q34690708 | A review of a priori regression models for warfarin maintenance dose prediction |
| Q40665013 | A systematic analysis and comparison of warfarin initiation strategies |
| Q30370833 | APOE ε variants increase risk of warfarin-related intracerebral hemorrhage. |
| Q35023701 | Addressing phenoconversion: the Achilles' heel of personalized medicine |
| Q38663764 | Advances in the Pharmacogenomics of Adverse Drug Reactions. |
| Q39088514 | Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. |
| Q47547673 | Algorithms for monitoring warfarin use: Results from Delphi Method |
| Q47622750 | An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review |
| Q50657730 | An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance. |
| Q33651712 | An integrated approach to defining genetic and environmental determinants for major clinical outcomes involving vitamin D. |
| Q42701943 | Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR. |
| Q30999121 | Analyzing the potential for incorrect haplotype calls with different pharmacogenomic assays in different populations: a simulation based on 1000 Genomes data |
| Q89233044 | Anticoagulants: What is new and what is the standard? |
| Q39053849 | Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach |
| Q45925530 | Anticoagulation therapy: genotype-guided anticoagulation therapy-the jury is still out. |
| Q38758788 | Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy |
| Q48901873 | Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization. |
| Q56607936 | Atrial fibrillation |
| Q36573086 | Attitudes of clinicians following large-scale pharmacogenomics implementation |
| Q35076456 | Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists |
| Q36953147 | Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association |
| Q49612005 | Benefit of pre-emptive pharmacogenetic information on clinical outcome. |
| Q30699715 | Bringing clinical pharmacogenomics information to pharmacists: A qualitative study of information needs and resource requirements |
| Q36930041 | CYP2C19 drug-drug and drug-gene interactions in ED patients |
| Q41478624 | CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy |
| Q89556414 | CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients |
| Q57585515 | CYP450 genotype and pharmacogenetic association studies: a critical appraisal |
| Q36696635 | Cardiovascular Pharmacogenomics--Implications for Patients With CKD. |
| Q57293266 | Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White? |
| Q38520990 | Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner |
| Q90652947 | Cardiovascular Precision Medicine in the Genomics Era |
| Q38974781 | Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine |
| Q26801183 | Cardiovascular pharmacogenomics: current status and future directions |
| Q38169969 | Cardiovascular pharmacogenomics: expectations and practical benefits |
| Q64951932 | Cases in Precision Medicine: The Role of Pharmacogenetics in Precision Prescribing. |
| Q39611892 | Challenges of development and implementation of point of care pharmacogenetic testing. |
| Q28082835 | Challenges to integrating pharmacogenetic testing into medication therapy management |
| Q37155053 | Clinical Application of Pharmacogenetics: Where are We Now? |
| Q93162370 | Clinical Model for Predicting Warfarin Sensitivity |
| Q38961083 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update |
| Q57293945 | Clinical Pharmacogenomics: Applications in Nephrology |
| Q39013613 | Clinical and regulatory considerations in pharmacogenetic testing. |
| Q46889272 | Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement |
| Q35126221 | Closing the gap between knowledge and clinical application: challenges for genomic translation |
| Q35679753 | Comparative effectiveness research and demonstrating clinical utility for molecular diagnostic tests |
| Q92782907 | Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis |
| Q47305572 | Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population |
| Q39018202 | Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients |
| Q37473370 | Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study |
| Q48690350 | Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System. |
| Q86299920 | Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control |
| Q53231509 | Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions. |
| Q39703517 | Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden |
| Q58558658 | Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients |
| Q38640906 | Critical Review and Update on the Treatment of Acute and Chronic Pulmonary Embolism |
| Q38197434 | Current concepts and clinical applications of stroke genetics |
| Q48069953 | Defining 'medical necessity' in an age of personalised medicine: A view from Canada |
| Q50775977 | Design and evaluation of a pharmacogenomics information resource for pharmacists. |
| Q34078825 | Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses |
| Q40862073 | Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration |
| Q37156736 | Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing |
| Q47688705 | Development of neuro-fuzzy model to explore gene-nutrient interactions modulating warfarin dose requirement |
| Q35827874 | Do physicians think genomic medicine will be useful for patient care? |
| Q51107902 | Dosage individualization of warfarin using artificial neural networks. |
| Q39034538 | Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes |
| Q34154939 | Drug-gene interactions: inherent variability in drug maintenance dose requirements |
| Q41535294 | Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands |
| Q26797183 | Economic evaluations of personalized medicine: existing challenges and current developments |
| Q33935409 | Edoxaban: an update on the new oral direct factor Xa inhibitor |
| Q34295187 | Educating orally anticoagulated patients in drug safety: a cluster-randomized study in general practice |
| Q46927387 | Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm |
| Q90162386 | Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals |
| Q89619881 | Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting |
| Q48580819 | Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. |
| Q93072133 | Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial |
| Q51815855 | Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. |
| Q38809948 | Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients |
| Q27026134 | Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis |
| Q53748314 | Emerging Role of Precision Medicine in Cardiovascular Disease. |
| Q58590457 | Ensemble of machine learning algorithms using the stacked generalization approach to estimate the warfarin dose |
| Q55379283 | Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine. |
| Q36195396 | Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial |
| Q39173298 | Evidence and resources to implement pharmacogenetic knowledge for precision medicine |
| Q35762508 | Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. |
| Q37703583 | Evidence for extensive pleiotropy among pharmacogenes |
| Q50955265 | Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. |
| Q38261133 | Features of electronic health records necessary for the delivery of optimized anticoagulant therapy: consensus of the EHR Task Force of the New York State Anticoagulation Coalition |
| Q30359686 | Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association |
| Q33760056 | Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome |
| Q42255919 | Genes affecting warfarin response-interactive or additive? |
| Q92206503 | Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis |
| Q57166441 | Genetic Predisposition to Neuroblastoma |
| Q38529234 | Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis |
| Q43113299 | Genetic determinants of variability in warfarin response after the dose-titration phase. |
| Q40637492 | Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy |
| Q28601852 | Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics |
| Q38203394 | Genetic testing in cardiovascular diseases |
| Q38867357 | Genetic testing to guide warfarin dosing: Impact of direct oral anticoagulants. |
| Q34284362 | Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. |
| Q33693846 | Genetic-based prediction of disease traits: prediction is very difficult, especially about the future |
| Q49142379 | Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. |
| Q40367486 | Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. |
| Q36068687 | Genome-wide association study of warfarin maintenance dose in a Brazilian sample |
| Q38292930 | Genomic architecture of pharmacological efficacy and adverse events |
| Q35006973 | Genotype and risk of major bleeding during warfarin treatment |
| Q50978962 | Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials. |
| Q36393911 | Genotype-based clinical trials in cardiovascular disease |
| Q38321269 | Genotype-guided coumarin dosing: where are we now and where do we need to go next? |
| Q38233757 | Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials |
| Q89478668 | Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial |
| Q58827166 | Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials |
| Q35223184 | Global epidemiology of atrial fibrillation |
| Q28066527 | Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism |
| Q37251490 | Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association |
| Q56968101 | Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial) |
| Q41729767 | Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis |
| Q52814257 | Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient. |
| Q39291966 | Identification of novel variants associated with warfarin stable dosage by use of a two-stage extreme phenotype strategy |
| Q26787099 | Impact of New Genomic Technologies on Understanding Adverse Drug Reactions |
| Q64111486 | Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement |
| Q34147916 | Implementation and utilization of genetic testing in personalized medicine |
| Q64065861 | Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study |
| Q54374494 | Implementation of inpatient models of pharmacogenetics programs. |
| Q39034897 | Implementing Precision Medicine: The Ethical Challenges |
| Q34436487 | Improved drug therapy: triangulating phenomics with genomics and metabolomics. |
| Q36367834 | Improving postapproval drug safety surveillance: getting better information sooner |
| Q38799910 | Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients |
| Q46293630 | Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai |
| Q28650281 | Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics |
| Q36599112 | Integrating electronic health record genotype and phenotype datasets to transform patient care |
| Q92102522 | Integrating pharmacogenetic testing into primary care |
| Q90330782 | Integration analysis of metabolites and single nucleotide polymorphisms improves the prediction of drug response of celecoxib |
| Q48972423 | International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events. |
| Q50095064 | Interview about the GIFT Trial, Pharmacogenetics, and Warfarin. |
| Q47669713 | Is your love in vain? On associations between genotypes, drug concentrations and clinical outcomes in pharmacogenomic research |
| Q46092410 | Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing |
| Q34879739 | Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area |
| Q36370325 | Leveraging genomic data in smoking cessation trials in the era of Precision Medicine: Why and how. |
| Q49110792 | Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials. |
| Q47728750 | Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists. |
| Q38730837 | Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research |
| Q39041135 | Meaningful use and clinical utility of preemptive pharmacogenetic testing: (re)view from a CYP2D6 poor metabolizer |
| Q30808861 | Medical genomics: Gather and use genetic data in health care |
| Q36015458 | Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin |
| Q51072095 | Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. |
| Q45362158 | Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches |
| Q38792475 | Navigating pleiotropy in precision medicine: pharmacogenes from trauma to behavioral health |
| Q44783345 | New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? |
| Q33364524 | New pieces to an old puzzle: identifying the warfarin-binding site that prevents clotting |
| Q28385820 | News from the NIH: potential contributions of the behavioral and social sciences to the precision medicine initiative |
| Q38212962 | Novel anticoagulants for stroke prevention in patients with atrial fibrillation |
| Q47277562 | Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics |
| Q64269386 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity |
| Q38796447 | Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose |
| Q88487480 | Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation |
| Q42383190 | Opportunities and limitations: the value of pharmacogenetics in clinical practice. |
| Q41014816 | Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm |
| Q90029274 | Optimizing quality care for the oral vitamin K antagonists (VKAs) |
| Q94539429 | Oral Anticoagulants and Precision Medicine: Something Old, Something New |
| Q38194842 | Oral anticoagulants for Asian patients with atrial fibrillation |
| Q37100793 | Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literature |
| Q47345659 | PRECISION MEDICINE: FROM DIPLOTYPES TO DISPARITIES TOWARDS IMPROVED HEALTH AND THERAPIES. |
| Q36417380 | Parsing interindividual drug variability: an emerging role for systems pharmacology |
| Q46418723 | Patients benefit from genetics-guided coumarin anticoagulant therapy |
| Q41656591 | Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism |
| Q48536840 | Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical Trials. |
| Q40956598 | Personalized Drug Dosage - Closing the Loop |
| Q26822796 | Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics |
| Q38254326 | Personalized genomes and cardiovascular disease |
| Q36965849 | Personalized medicine in thrombosis: back to the future |
| Q38756015 | Personalized medicine: Genetic risk prediction of drug response |
| Q39000790 | Personalizing Bridging Anticoagulation in Patients with Nonvalvular Atrial Fibrillation-a Microsimulation Analysis |
| Q38731079 | Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways |
| Q38782191 | Pharmacogenetic Implementation Lessons From the "Real World". |
| Q38419534 | Pharmacogenetic Markers of Drug Efficacy and Toxicity |
| Q38778546 | Pharmacogenetic Predictors of Response |
| Q38214388 | Pharmacogenetic biomarkers for predicting drug response. |
| Q40368578 | Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial |
| Q42345777 | Pharmacogenetics and precision medicine: Is inflammation a covert threat to effective genotype-based therapy? |
| Q47130405 | Pharmacogenetics in Cardiovascular Medicine |
| Q34458720 | Pharmacogenetics in Jewish populations. |
| Q64968253 | Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine. |
| Q47965250 | Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes |
| Q38262829 | Pharmacogenetics of coumarin anticoagulants in Brazilians |
| Q35661209 | Pharmacogenetics of drug-metabolizing enzymes in US Hispanics |
| Q33986293 | Pharmacogenetics of heart failure |
| Q57805160 | Pharmacogenetics of warfarin dosing in patients of African and European ancestry |
| Q34402967 | Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. |
| Q35870028 | Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials |
| Q27008320 | Pharmacogenetics-based warfarin dosing in children |
| Q47776901 | Pharmacogenetics: a general review on progress to date |
| Q47357309 | Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments |
| Q90045527 | Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation |
| Q46518961 | Pharmacogenomic testing and response to warfarin |
| Q92506521 | Pharmacogenomics |
| Q48125765 | Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen |
| Q91740942 | Pharmacogenomics In Pharmacy Practice: Current Perspectives |
| Q38607878 | Pharmacogenomics and Implications for Nursing Practice |
| Q37719025 | Pharmacogenomics and adverse drug reactions in children. |
| Q35769279 | Pharmacogenomics in cardiology--genetics and drug response: 10 years of progress |
| Q27335306 | Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas |
| Q47570862 | Pharmacogenomics of CYP2C9: Functional and Clinical Considerations |
| Q27015722 | Pharmacogenomics of hypertension and heart disease |
| Q35961759 | Pharmacogenomics, human genetic diversity and the incorporation and rejection of color/race in Brazil |
| Q38217626 | Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program |
| Q39029202 | Pharmacological management of pulmonary embolism |
| Q38380461 | Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. |
| Q55080660 | Physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education. |
| Q53665734 | Pilot study: incorporation of pharmacogenetic testing in medication therapy management services. |
| Q34791041 | Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. |
| Q40629929 | Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms |
| Q38214960 | Potential antidotes for reversal of old and new oral anticoagulants |
| Q37632365 | Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient: Role of a Novel NQO1*2 Polymorphism. |
| Q35809920 | Pragmatic and Ethical Challenges of Incorporating the Genome into the Electronic Medical Record |
| Q39224845 | Precision Cardiovascular Medicine: State of Genetic Testing. |
| Q91468339 | Precision dosing of warfarin: open questions and strategies |
| Q42507839 | Precision medicine informatics |
| Q47566249 | Precision medicine: does ethnicity information complement genotype-based prescribing decisions? |
| Q39561868 | Predicting prolonged dose titration in patients starting warfarin. |
| Q35806323 | Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support. |
| Q94410300 | Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing |
| Q87318611 | Progress in pharmacogenomics: bridging the gap from research to practice |
| Q28083100 | Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity |
| Q28652270 | Progress towards the integration of pharmacogenomics in practice |
| Q53817817 | Pyrosequencing of the CYP2C9 -1766T>C polymorphism as a means of detecting the CYP2C9*8 allele. |
| Q40083909 | Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users |
| Q38384338 | Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. |
| Q35884265 | Race influences warfarin dose changes associated with genetic factors. |
| Q36717256 | Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users |
| Q38644870 | Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments |
| Q38953706 | Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial |
| Q64089122 | Relationship between a Weighted Multi-Gene Algorithm and Blood Pressure Control in Hypertension |
| Q27028131 | Respiratory review of 2014: pulmonary thromboembolism |
| Q41756168 | Returning pharmacogenetic secondary findings from genome sequencing: let's not put the cart before the horse. |
| Q35753465 | Revisiting Warfarin Dosing Using Machine Learning Techniques. |
| Q33570878 | Revitalizing personalized medicine: respecting biomolecular complexities beyond gene expression |
| Q38941642 | Role of pharmacogenetics in public health and clinical health care: a SWOT analysis |
| Q33557032 | STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION |
| Q50693478 | Simulating sequential multiple assignment randomized trials to generate optimal personalized warfarin dosing strategies. |
| Q38217692 | Strategies to reduce bleeding risk in acute coronary syndromes and percutaneous coronary intervention: new and emerging pharmacotherapeutic considerations. |
| Q90070321 | Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients |
| Q90575870 | Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases |
| Q37091133 | Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity |
| Q39123582 | The Application of Genomics in Diabetes: Barriers to Discovery and Implementation |
| Q64067566 | The Effect of Genetically Guided Mathematical Prediction and the Blood Pressure Response to Pharmacotherapy in Hypertension Patients |
| Q48665970 | The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin. |
| Q36228428 | The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review |
| Q35868100 | The Impact of Inpatient Versus Outpatient Initiation on Early Warfarin Dosing |
| Q36794572 | The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone |
| Q92811652 | The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology |
| Q88910051 | The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics |
| Q54961174 | The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. |
| Q47837577 | The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin |
| Q55258487 | The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study. |
| Q57500191 | The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement |
| Q47929031 | The challenges of implementing pharmacogenomic testing in the clinic. |
| Q34644992 | The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology |
| Q58563966 | The impact of R353Q genetic polymorphism in coagulation factor VII on the initial anticoagulant effect exerted by warfarin |
| Q50199930 | The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants. |
| Q50193711 | The year in cardiology 2017: arrhythmias and cardiac devices. |
| Q47920440 | Time to revisit warfarin pharmacogenetics |
| Q50950032 | Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. |
| Q27025306 | Use of contemporary genetics in cardiovascular diagnosis |
| Q30978916 | Use of genetic data to guide therapy in arterial disease |
| Q57646588 | User considerations in assessing pharmacogenomic tests and their clinical support tools |
| Q38287616 | Using HLA typing to support patients with cancer. |
| Q38312159 | Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience |
| Q37552063 | VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients |
| Q47345423 | VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study. |
| Q43936573 | Validation of patient-reported warfarin dose in a prospective incident cohort study |
| Q40880691 | Variation in warfarin prescribing and dosing in the UK: a national survey of anticoagulation clinics |
| Q89217812 | Venous thrombosis |
| Q35146916 | Verification of pharmacogenetics-based warfarin dosing algorithms in Han-Chinese patients undertaking mechanic heart valve replacement |
| Q33770184 | Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study |
| Q38979667 | Warfarin Dosing Algorithms Underpredict Dose Requirements in Patients Requiring ≥7 mg Daily: A Systematic Review and Meta-analysis |
| Q36689643 | Warfarin Dosing Algorithms and the Need for Human Intervention |
| Q50635306 | Warfarin Pharmacogenetics Reevaluated: Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials. |
| Q38696567 | Warfarin Pharmacogenomics in Diverse Populations. |
| Q93092167 | Warfarin Quality Metrics for Hospitalized Older Adults |
| Q35678294 | Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII |
| Q42088252 | Warfarin dose requirements in a patient with the CYP2C9*14 allele |
| Q91063311 | Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients - a randomized, prospective study |
| Q93224302 | Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9 |
| Q33946309 | Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing? |
| Q34785072 | Warfarin pharmacogenetics |
| Q38221329 | Warfarin pharmacogenetics: to genotype or not to genotype, that is the question |
| Q35884246 | Warfarin pharmacogenomics and African ancestry |
| Q38543302 | Warfarin pharmacogenomics: current best evidence |
| Q39368933 | Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile |
| Q57302446 | Warfarin: The End or the End of One Size Fits All Therapy? |
| Q42602646 | Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. |
| Q48385505 | Will personalized drugs for cardiovascular disease become an option? - Defining 'Evidence-based personalized medicine' for its implementation and future use. |
| Q88150087 | [Current state and trend of precision medicine in thrombosis and hemostasis] |
| Q38812513 | e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study. |
Search more.